Brolucizumab
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized |
| Target | Vascular endothelial growth factor A (VEGFA) |
| Clinical data | |
| Trade names | Beovu |
| Other names | brolucizumab-dbll, RTH258, DLX1008 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620001 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravitreal |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1164H1768N310O372S7 |
| Molar mass | 26281.17 g·mol−1 |
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).[6][5]
The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision).[6][5] The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye).[6][5]
Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A).[6] VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.[6][5]
History
[edit]Brolucizumab is approved by the US Food and Drug Administration (FDA) for use in ophthalmology.[7][8]
Brolucizumab successfully completed phase III development in wet age-related macular degeneration (AMD) meeting the primary efficacy endpoint of non-inferiority to aflibercept in mean change in best corrected visual acuity (BCVA) from baseline to week 48. Furthermore, brolucizumab demonstrated superiority to aflibercept in key secondary endpoint measures of disease activity in wet age-related macular degeneration, a leading cause of blindness in two head-to-head pivotal Phase III studies.[9][10][11][12]
In October 2019, Novartis announced that the US Food and Drug Administration (FDA) approved brolucizumab injection for the treatment of wet age-related macular degeneration.[7]
The FDA approved brolucizumab based on evidence from two clinical trials (Trial 1/ NCT02307682 and Trial 2/NCT02434328) of 1459 participants, 50–97 years old, with wet AMD. The trials were conducted at 336 sites in the United States, Canada, Central and South America, European countries, Israel, Turkey, Australia, New Zealand, Japan, South Korea, Singapore, Taiwan, and Vietnam.[13]
Brolucizumab was approved for use in the European Union in February 2020.[6]
Society and culture
[edit]Safety concerns
[edit]In February 2020, the American Society of Retina Specialists reported side effects of brolucizumab, specifically in 14 cases of retinal vasculitis reported in people using brolucizumab, 11 of the cases were occlusive retinal vasculitis that can lead to vision loss.[14][15] Novartis responded with a statement standing behind the efficacy of Beovu.[16][17]
In June 2020, the FDA approved an updated prescription label for brolucizumab that included additional safety information—specifically including the characterization of adverse events, retinal vasculitis and retinal vascular occlusion, as part of the spectrum of intraocular inflammation observed in HAWK (NCT02307682)[11] and HARRIER (NCT02434328)[12] clinical trials and noted in the original prescribing information.[18]
Names
[edit]Brolucizumab is the International Nonproprietary Name (INN) and the United States Adopted Name (USAN)[19][20]
Research
[edit]Non-ophthalmology indications are under investigation, under the name DLX1008. DLX1008 is under preclinical development for Kaposi sarcoma[21] and glioblastoma.[22]
References
[edit]- ^ Medicine registrations Archived 28 June 2023 at the Wayback Machine Australian Government
- ^ "Beovu Product information". Health Canada. 25 April 2012. Archived from the original on 8 August 2024. Retrieved 29 May 2022.
- ^ "Summary Basis of Decision (SBD) for Beovu". Health Canada. 23 October 2014. Archived from the original on 23 June 2023. Retrieved 29 May 2022.
- ^ "Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 9 March 2020. Archived from the original on 24 September 2020. Retrieved 3 May 2020.
- ^ a b c d e "Beovu- brolucizumab injection, solution". DailyMed. 13 January 2020. Archived from the original on 9 January 2021. Retrieved 3 May 2020.
- ^ a b c d e f g "Beovu EPAR". European Medicines Agency (EMA). 10 December 2019. Archived from the original on 8 November 2020. Retrieved 3 May 2020.
This article incorporates text from this source, which is in the public domain.
- ^ a b "Novartis receives FDA approval for Beovu, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept" (Press release). Novartis. Archived from the original on 13 September 2021. Retrieved 16 October 2019.
- ^ "Drug Approval Package: Beovu (brolucizumab-dbll)". U.S. Food and Drug Administration (FDA). 4 November 2019. Archived from the original on 17 November 2019. Retrieved 17 November 2019.
- ^ Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. (April 2019). "HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration". Ophthalmology. 127 (1): 72–84. doi:10.1016/j.ophtha.2019.04.017. PMID 30986442.
- ^ Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. (May 2016). "Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study". Ophthalmology. 123 (5): 1080–9. doi:10.1016/j.ophtha.2015.12.030. PMID 26906165.
- ^ a b Clinical trial number NCT02307682 for "Efficacy and Safety of RTH258 Versus Aflibercept – Study 1 (HAWK)" at ClinicalTrials.gov
- ^ a b Clinical trial number NCT02434328 for "Efficacy and Safety of RTH258 Versus Aflibercept – Study 2 (HARRIER)" at ClinicalTrials.gov
- ^ "Drug Trials Snapshots: BEOVU". U.S. Food and Drug Administration. 7 October 2019. Archived from the original on 17 November 2019. Retrieved 17 November 2019. This article incorporates text from this source, which is in the public domain.
- ^ "Novartis Responds to ASRS Note Raising Safety Concerns With Wet AMD Drug Beovu". Eyewire News. 25 February 2020. Archived from the original on 4 November 2021. Retrieved 27 April 2020.
- ^ "Novartis' hot new eye drug Beovu tied to potential vision loss: experts". FiercePharma. 24 February 2020. Archived from the original on 27 July 2021. Retrieved 27 April 2020.
- ^ Sagonowsky E (2 March 2020). "Novartis stands behind Beovu's safety, benefits after vision-loss warning". FiercePharma. Archived from the original on 1 November 2020. Retrieved 27 April 2020.
- ^ "Novartis provides update on use and safety of Beovu (brolucizumab)". Novartis. 28 April 2020. Archived from the original on 17 October 2021. Retrieved 27 April 2020.
- ^ "BRIEF-U.S. FDA Approves Novartis' Updated Beovu Label - Statement". Reuters. 11 June 2020. Archived from the original on 11 June 2020. Retrieved 11 June 2020.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brolucizumab Archived 15 August 2016 at the Wayback Machine, American Medical Association.
- ^ World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): proposed INN: list 112". WHO Drug Information. 28 (4): 493. hdl:10665/331100.
- ^ Eason AB, Sin SH, Szabó E, Phillips DJ, Droste M, Shamshiev A, et al. (2018). "Abstract 4: Antitumor activity of DLX1008, a single chain antibody fragment binding to VEGF-A, in in vivo preclinical models of Kaposi sarcoma and glioblastoma". Cancer Research. 78 (13 Supplement): 4. doi:10.1158/1538-7445.AM2018-4. ISSN 0008-5472. S2CID 81317833.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ Szabó E, Phillips DJ, Droste M, Marti A, Kretzschmar T, Shamshiev A, et al. (May 2018). "Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models". The Journal of Pharmacology and Experimental Therapeutics. 365 (2): 422–429. doi:10.1124/jpet.117.246249. PMID 29507055.
